Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Vaxcyte's experimental pneumococcal vaccine generated immune responses comparable to Pfizer and Merck vaccines in a Phase 3 trial, positioning it to compete in the lucrative vaccine market.